Slowing of the Progression of Atherosclerosis
In the Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)study, the effect of therapy with rosuvastatin calcium on carotid atherosclerosis was assessed by B-mode ultrasonography in patients with elevated LDL-C, at low risk (Framingham risk <10% over ten years) for symptomatic coronary artery disease and with subclinical atherosclerosis as evidenced by carotid intimal-medial thickness (cIMT). In this double-blind, placebo-controlled clinical study 984 adult patients were randomized (of whom 876 were analyzed) in a 5:2 ratio to rosuvastatin calcium 40 mg or placebo once daily. Ultrasonograms of the carotid walls were used to determine the annualized rate of change per patient from baseline to two years in mean maximum cIMT of 12 measured segments. The estimated difference in the rate of change in the maximum cIMT analyzed over all 12 carotid artery sites between patients treated with rosuvastatin calcium and placebo-treated patients was -0.0145 mm/year (95% CI –0.0196, – 0.0093; p<0.0001).
The annualized rate of change from baseline for the placebo group was +0.0131 mm/year (p<0.0001). The annualized rate of change from baseline for the group treated with rosuvastatin calcium was -0.0014 mm/year (p=0.32).
At an individual patient level in the group treated with rosuvastatin calcium, 52.1% of patients demonstrated an absence of disease progression (defined as a negative annualized rate of change), compared to 37.7% of patients in the placebo group.
HeFH in Adults
In a study of adult patients with HeFH (baseline mean LDL of 291 mg/dL), patients were randomized to rosuvastatin calcium 20 mg or atorvastatin 20 mg. The dose was increased at 6-week intervals. Significant LDL-C reductions from baseline were seen at each dose in both treatment groups (see Table 12).
Table 12: LDL-C Percent Change from Baseline
Rosuvastatin calcium (n=435)
LS Mean 1
(95% CI)
Atorvastatin (n=187)
LS Mean 1 (95% CI)
Week 6
20 mg
-47% (-49%, -46%)
-38% (-40%, -36%)
Week 12
40 mg
-55% (-57%, -54%)
-47% (-49%, -45%)
Week 18
80 mg
NA
-52% (-54%, -50%)
1LS Means are least square means adjusted for baseline LDL-C
HeFH in Pediatric Patients
In a double-blind, randomized, multicenter, placebo-controlled, 12-week study, 176 (97 male and 79 female) pediatric patients with HeFH were randomized to rosuvastatin 5 mg, 10 mg or 20 mg or placebo daily. Patients ranged in age from 10 to 17 years (median age of 14 years) with approximately 30% of the patients 10 to 13 years and approximately 17%, 18%, 40%, and 25% at Tanner stages II, III, IV, and V, respectively. Females were at least 1-year postmenarche. Mean LDL-C at baseline was 233 mg/dL (range of 129 to 399). The 12-week double-blind phase was followed by a 40-week open-label dose-titration phase, where all patients (n=173) received 5 mg, 10 mg or 20 mg rosuvastatin daily.
Rosuvastatin significantly reduced LDL-C (primary end point), total cholesterol and ApoB levels at each dose compared to placebo. Results are shown in Table 13 below.
Table 13: Lipid-Modifying Effects of Rosuvastatin calcium in Pediatric Patients 10 to 17 years of Age with HeFH (Least-Squares Mean Percent Change from Baseline To Week 12)
Dose (mg)
N
LDL-C
HDL-C
Total-C
TG 1
ApoB
Placebo
46
-1%
+7%
0%
-7%
-2%
5
42
-38%
+4% 2
-30%
-13% 2
-32%
10
44
-45%
+11% 2
-34%
-15% 2
-38%
20
44
-50%
+9% 2
-39%
16% 2
-41%
1Median percent change
2 Difference from placebo not statistically significant
Rosuvastatin was also studied in a two-year open-label, uncontrolled, titration-to-goal trial that included 175 pediatric patients with HeFH who were 8 to 17 years old (79 males and 96 females). All patients had a documented genetic defect in the LDL receptor or in ApoB. Approximately 89% were White, 7% were Asian, 1% were Black or African American, and fewer than 1% were Hispanic or Latino ethnicity. Mean LDL-C at baseline was 236 mg/dL. Fifty-eight (33%) patients were prepubertal at baseline. The starting rosuvastatin dosage for all pediatric patients was 5 mg once daily. Pediatric patients aged 8 to less than 10 years (n=41 at baseline) could titrate to a maximum dosage of 10 mg once daily, and pediatric patients aged 10 to 17 years could titrate to a maximum dosage of 20 mg once daily.
The reductions in LDL-C from baseline were generally consistent across age groups within the trial as well as with previous experience in both adult and pediatric controlled trials.
HoFH in Adult and Pediatric Patients
In an open-label, forced-titration study, HoFH patients (n=40, 8 to 63 years) were evaluated for their response to rosuvastatin calcium 20 to 40 mg titrated at a 6-week interval. In the overall population, the mean LDL-C reduction from baseline was 22%. About one-third of the patients benefited from increasing their dose from 20 mg to 40 mg with further LDL-C lowering of greater than 6%. In the 27 patients with at least a 15% reduction in LDL-C, the mean LDL-C reduction was 30% (median 28% reduction). Among 13 patients with an LDL-C reduction of <15%, 3 had no change or an increase in LDL-C. Reductions in LDL-C of 15% or greater were observed in 3 of 5 patients with known receptor negative status.
HoFH in Pediatric Patients
Rosuvastatin calcium was studied in a randomized, double-blind, placebo-controlled, multicenter, crossover study in 14 pediatric patients with HoFH. The study included a 4-week dietary lead-in phase during which patients received rosuvastatin calcium 10 mg daily, a cross-over phase that included two 6-week treatment periods with either rosuvastatin calcium 20 mg or placebo in random order, followed by a 12-week open-label phase during which all patients received rosuvastatin calcium 20 mg. Patients ranged in age from 7 to 15 years of age (median 11 years), 50% were male, 71% were White, 21% were Asian, 7% were Black or African American, and no patients were of Hispanic or Latino ethnicity. Fifty percent were on apheresis therapy and 57% were taking ezetimibe. Patients who entered the study on apheresis therapy or ezetimibe continued the treatment throughout the entire study. Mean LDL-C at baseline was 416 mg/dL (range 152 to 716 mg/dL). A total of 13 patients completed both treatment periods of the randomized cross-over phase; one patient withdrew consent due to inability to have blood drawn during the cross-over phase.
Rosuvastatin calcium 20 mg significantly reduced LDL-C, total cholesterol, ApoB, and non-HDL-C compared to placebo (see Table 14).
Table 14: Lipid-Modifying Effects of Rosuvastatin calcium in Pediatric Patients 7 to 15 years of Age with HoFH After 6 Weeks
Placebo (N=13)
Rosuvastatin calcium
20 mg (N=13)
Percent difference (95% CI)
LDL-C (mg/dL)
481
396
-22.3% (-33.5, -9.1) 1
Total-C (mg/dL)
539
448
-20.1% (-29.7, -9.1) 2
Non-HDL-C (mg/dL)
505
412
-22.9% (-33.7, -10.3) 2
ApoB (mg/dL)
268
235
-17.1% (-29.2, -2.9) 3
% Difference estimates are based on transformations of the estimated mean difference in log LDL measurements between rosuvastatin calcium and placebo using a mixed model adjusted for study period 1p=0.005, 2p=0.003, 3p=0.024
Primary Dysbetalipoproteinemia in Adults
In a randomized, multicenter, double-blind cross-over study, 32 adult patients (27 with є2/є2 and 4 with apo E mutation [Arg145Cys] with primary dysbetalipoproteinemia entered a 6-week dietary lead-in period on the NCEP Therapeutic Lifestyle Change (TLC) diet. Following dietary lead-in, patients were randomized to a sequence of treatments for 6 weeks each: rosuvastatin 10 mg followed by rosuvastatin 20 mg or rosuvastatin 20 mg followed by rosuvastatin 10 mg. Rosuvastatin calcium reduced non-HDL-C (primary end point) and circulating remnant lipoprotein levels. Results are shown in the table below.
Table 15: Lipid-Modifying Effects of Rosuvastatin calcium 10 mg and 20 mg in Adult Patients with Primary Dysbetalipoproteinemia (Type III hyperlipoproteinemia) After Six Weeks by Median Percent Change (95% CI) from Baseline (N=32)
Median at Baseline (mg/dL)
Median percent change from baseline (95% CI) rosuvastatin calcium 10 mg
Median percent change from baseline (95% CI) rosuvastatin calcium 20 mg
Total-C
342.5
-43.3
(-46.9, -37.5)
-47.6
(-51.6, -42.8)
Triglycerides
503.5
-40.1
(-44.9, -33.6)
-43.0
(-52.5, -33.1)
Non-HDL-C
294.5
-48.2
(-56.7, -45.6)
-56.4
(-61.4, -48.5)
VLDL-C + IDL-C
209.5
-46.8
(-53.7, -39.4)
-56.2
(-67.7, -43.7)
LDL-C
112.5
-54.4
(-59.1, -47.3)
-57.3
(-59.4, -52.1)
HDL-C
35.5
10.2
(1.9, 12.3)
11.2
(8.3, 20.5)
RLP-C
82.0
-56.4
(-67.1, -49.0)
-64.9
(-74.0, -56.6)
Apo-E
16.0
-42.9
(-46.3, -33.3)
-42.5
(-47.1, -35.6)
Hypertriglyceridemia in Adults
In a double-blind, placebo-controlled study in adult patients with baseline TG levels from 273 to 817 mg/dL, rosuvastatin calcium given as a single daily dose (5 to 40 mg) over 6 weeks significantly reduced serum TG levels (see Table 16).
Table 16: Lipid-Modifying Effect of Rosuvastatin calcium in Adult Patients with Primary Hypertriglyceridemia After Six Weeks by Median (Min, Max) Percent Change from Baseline to Week 6
Dose
Placebo (n=26)
Rosuvastatin calcium
5 mg
(n=25)
Rosuvastatin calcium
10 mg
(n=23)
Rosuvastatin calcium
20 mg
(n=27)
Rosuvastatin calcium
40 mg
(n=25)
Triglycerides
1 (-40, 72)
-21 (-58, 38)
-37 (-65, 5)
-37 (-72, 11)
-43 (-80, -7)
Non-HDL-C
2 (-13, 19)
-29 (-43, -8)
-49 (-59, -20)
-43 (-74, 12)
-51 (-62, -6)
Total-C
1 (-13, 17)
-24 (-40, -4)
-40 (-51, -14)
-34 (-61, -11)
-40 (-51, -4)
LDL-C
5 (-30, 52)
-28 (-71, 2)
-45 (-59, 7)
-31 (-66, 34)
-43 (-61, -3)
HDL-C
-3 (-25, 18)
3 (-38, 33)
8 (-8, 24)
22 (-5, 50)
17 (-14, 63)
PATIENT INFORMATION Rosuvastatin (roe soo” va stat’ in) Tablets, USP for oral use |
Read this Patient Information carefully before you start taking rosuvastatin tablets and each time you get a refill. If you have any questions about rosuvastatin tablets, ask your healthcare provider. Only your healthcare provider can determine if rosuvastatin tablets is right for you.
|
What are Rosuvastatin tablets?
Rosuvastatin tablets are a prescription medicine that contains a cholesterol-lowering medicine called rosuvastatin.
• Rosuvastatin tablets are used:
o to reduce the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, or the need for procedures to improve blood flow to the heart called arterial revascularization, in adults who do not have known heart disease but do have certain additional risk factors.
o along with diet to:
o lower the level of low-density lipoprotein (LDL-C) cholesterol or “bad” cholesterol in adults with primary hyperlipidemia.
o slow the buildup of fatty deposits (plaque) in the walls of blood vessels.
o treat adults and children 8 years of age and older with high blood cholesterol due to heterozygous familial hypercholesterolemia (HeFH) (an inherited condition that causes high levels of (LDL-C).
o along with other cholesterol lowering treatments or alone if such treatments are unavailable in adults and children 7 years of age and older with homozygous familial hypercholesterolemia (HoFH) (an inherited condition that causes high levels of LDL-C).
o along with diet for the treatment of adults with:
o primary dysbetalipoproteinemia (an inherited condition that causes high levels of cholesterol and fat).
o hypertriglyceridemia.
It is not known if rosuvastatin calcium is safe and effective in children younger than 8 years of age with HeFH or children younger than 7 years of age with HoFH or in children with other types of hyperlipidemias (other than HeFH or HoFH).
Do not take rosuvastatin tablets if you: |
• have liver problems.
• are allergic to rosuvastatin calcium or any of the ingredients in rosuvastatin tablets. See the end of this leaflet for a complete list of ingredients in rosuvastatin tablets.
|
Before you take rosuvastatin tablets, tell your healthcare provider about all of your medical conditions, including if you: • have unexplained muscle aches or weakness.
• have or have had kidney problems.
• have or have had liver problems.
• drink more than 2 glasses of alcohol daily.
• have thyroid problems.
• are of Asian descent.
• are pregnant or think you may be pregnant, or are planning to become pregnant. If you become pregnant while taking rosuvastatin tablets, call your healthcare provider right away to discuss your rosuvastatin tablets treatment.
• are breastfeeding. Rosuvastatin can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take rosuvastatin tablets. Do not breastfeed while taking rosuvastatin tablets.
Tell your healthcare provider about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider who prescribes rosuvastatin tablets if another healthcare provider increases the dose of another medicine you are taking. Rosuvastatin tablets may affect the way other medicines work, and other medicines may affect how rosuvastatin tablets works.
Especially tell your healthcare provider if you take:
• coumarin anticoagulants (medicines that prevent blood clots, such as warfarin)
• antacids (medicines you take for heartburn that contain aluminum and magnesium hydroxide
Taking rosuvastatin tablets with certain medicines may increase the risk of muscle problems.
Especially tell your healthcare provider if you take:
• cyclosporine (a medicine for your immune system)
• teriflunomide (a medicine used to treat relapsing remitting multiple sclerosis)
• enasidenib (a medicine used to treat acute myeloid leukemia)
• capmatinib (a medicine for the treatment of non-small cell lung cancer)
• fostamatinib (a medicine used to treat low platelet counts)
• febuxostat (a medicine used to treat and prevent high blood levels of uric acid)
• gemfibrozil (a fibric acid medicine for lowering cholesterol)
• tafamidis [used to treat cardiomyopathy (enlarged and thickened heart muscle)]
• anti-viral medicines including certain HIV or hepatitis C virus drugs such as:
o lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevir
o combination of
o sofosbuvir/velpatasvir/voxilaprevir
o dasabuvir/ombitasvir/paritaprevir/ritonavir
o elbasvir/grazoprevir
o sofosbuvir/velpatasvir
o glecaprevir/pibrentasvir
and
o
all other combinations with ledipasvir including ledipasvir/sofosbuvir
• darolutamide (a medicine for the treatment of prostate cancer)
• regorafenib (a medicine used to treat cancer of the colon and rectum)
• fibric acid derivatives (such as fenofibrate)
• ticagrelor (helps reduce the chance of a blood clot formation that can block a blood vessel)
• niacin or nicotinic acid
• colchicine (a medicine used to treat gout)
Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get new medicine.
|
How should I take rosuvastatin tablets? • Take rosuvastatin tablets exactly as your healthcare provider tells you to take it.
• Take rosuvastatin tablets, by mouth, 1 time each day, with or without food. Swallow the tablet whole.
• Rosuvastatin tablets can be taken at any time of day, with or without food.
•
Do notchange your dose or stop rosuvastatin tablets without talking to your healthcare provider, even if you are feeling well.
• Your healthcare provider may do blood tests to check your cholesterol levels before and during your treatment with rosuvastatin tablets. Your healthcare provider may change your dose of rosuvastatin tablets if needed.
• While taking rosuvastatin tablets, continue to follow your cholesterol-lowering diet and to exercise as your healthcare provider told you to.
• If you take a medicine called an antacid that contains a combination of aluminum and magnesium hydroxide, take rosuvastatin tablets at least 2 hours before you take the antacid.
• If you miss a dose of rosuvastatin tablets, take your next dose at your normal scheduled time.
Do not takean extra dose of rosuvastatin tablets.
• In case of an overdose, get medical help or contact a live Poison Center expert right away at 1800-222-1222. Advice is also available online at poisonhelp.org.
|
What are the possible side effects of rosuvastatin tablets?
Rosuvastatin tablets may cause serious side effects, including:
• Muscle pain, tenderness and weakness (myopathy). Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to death. Tell your healthcare provider right away if:
o you have unexplained muscle pain, tenderness, or weakness, especially if you have a fever or feel more tired than usual, while you take rosuvastatin tablets.
o you have muscle problems that do not go away even after your healthcare provider has told you to stop taking rosuvastatin tablets. Your healthcare provider may do further tests to diagnose the cause of your muscle problems.
Your chances of getting muscle problems are higher if you:
o are taking certain other medicines while you take rosuvastatin tablets (see “Especially tell your healthcare provider if you take”)
o are 65 years of age or older
o are of Asian descent
o have thyroid problems (hypothyroidism) that are not controlled
o have kidney problems
o are taking higher doses of rosuvastatin tablets
• Liver problems.Your healthcare provider may do blood tests to check your liver before you start taking rosuvastatin tablets and if you have symptoms of liver problems while you take rosuvastatin tablets. Call your healthcare provider right away if you have any of the following symptoms of liver problems:
o feel unusually tired or weak
o loss of appetite
o upper belly pain
o dark urine
o yellowing of your skin or the whites of your eyes
• Protein and blood in the urine. Rosuvastatin tablets may cause you to have protein and blood in your urine. If you develop protein or blood in your urine, your healthcare provider may decrease your dose of rosuvastatin tablets.
•
Increase in blood sugar (glucose) levels. Rosuvastatin tablets may cause an increase in your blood sugar levels.
The most common side effects may include headache, nausea, muscle aches and pains, weakness, and constipation.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
|
How should I store rosuvastatin tablets? • Store rosuvastatin tablets at room temperature, between 68°F to 77°F (20°C to 25°C) and in a dry place.
Keep rosuvastatin tablets and all medicines out of the reach of children. |
General Information about the safe and effective use of rosuvastatin tablets
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use rosuvastatin tablets for a condition for which it was not prescribed. Do not give rosuvastatin tablets to other people, even if they have the same medical condition you have. It may harm them.
You can ask your pharmacist or healthcare provider for information about rosuvastatin tablets that is written for health professionals.
|
What are the Ingredients in rosuvastatin tablets? Active Ingredient:rosuvastatin as rosuvastatin calcium
Inactive Ingredients:crospovidone, hypromellose, lactose monohydrate, magnesium stearate, mannitol, meglumine, microcrystalline cellulose, pregelatinized starch, titanium dioxide and triacetin. Additionally, 10 mg, 20 mg and 40 mg tablets contain FD&C red No. 40/allura red AC aluminum lake, FD&C blue No. 2/indigo carmine aluminum lake and FD&C yellow No.6/sunset yellow FCF aluminum lake.
For more information, go to www.novadozpharma.com or call 1-855-668-2369.
|
Repackaged and Distributed By:
Remedy Repack, Inc.
625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762
This Patient Information has been approved by the U.S. Food and Drug Administration Revised: 11/2024